Ligand Reports First Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall St ticks lower as markets monitor Hormuz situation; data awaited
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil rises 3% as Iran tempers hopes of Hormuz reopening
- Intel stock stumbles following blockbuster $15 billion equity offering
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Ligand Pharma (LGND) Tops Q1 EPS by 29c, Offers FY Guidance
May 3, 2021 4:57 PM EDTLigand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.41, $0.29 better than the analyst estimate of $1.12. Revenue for the quarter came in at $55.2 million versus the consensus estimate of $62.85 million.
GUIDANCE:
Ligand Pharma sees 2021 EPS of $6.15, versus the consensus of $6.17. Ligand Pharma... More
